^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IL4R (Interleukin 4 Receptor)

    i
    Other names: IL4R, Interleukin 4 Receptor, CD124, Interleukin-4 Receptor Subunit Alpha, IL-4 Receptor Subunit Alpha, Interleukin 13 Receptor, IL-4RA, IL4RA, Interleukin-4 Receptor Alpha Chain, IL-4R Subunit Alpha, CD124 Antigen, IL-4R-Alpha
    Associations

    News

    Trials
    9ms
    Single-cell analysis reveals potential therapeutic markers of peripheral blood mononuclear cells from bladder cancer patients. (PubMed, Braz J Med Biol Res)
    Neu-FCGR3B may play a detrimental role in the anti-tumor response and could emerge as a predictive marker for bladder cancer. Overall, these high-resolution transcriptomic data offer invaluable insights for identifying new therapeutic targets and biomarkers in bladder cancer immunotherapy.
    Journal • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD38 (CD38 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • ITGAE (Integrin Subunit Alpha E) • GZMK (Granzyme K) • MS4A1 (Membrane Spanning 4-Domains A1) • TCL1A (TCL1 Family AKT Coactivator A) • IL4R (Interleukin 4 Receptor) • STMN1 (Stathmin 1)
    |
    PD-L1 expression
    12ms
    Antagonizing Il10 and Il4 signaling via intracerebral decoy receptor expression attenuates Aβ accumulation. (PubMed, Acta Neuropathol Commun)
    Notably, neither Il10 nor sIl10R expression altered tau pathology in two tau transgenic models, despite robust expression and impacts on glial proliferation. Together, these data reveal that decoy receptor mediated targeting of physiological Il10 or Il4 signaling can beneficially impact amyloid deposition and thus represent novel immunomodulatory approaches for AD therapy.
    Journal • IO biomarker
    |
    IL10 (Interleukin 10) • IL4 (Interleukin 4) • IL4R (Interleukin 4 Receptor)
    over1year
    Dependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive Rhabdomyosarcoma. (PubMed, Oncogene)
    We additionally show that, in some FP-RMS, KDM3A also increases PAX3-FOXO1 levels. Together, our studies illuminate mechanisms of action of the KDM3A/ETS1 regulatory module, and reveal novel targetable mechanisms of PAX3-FOXO1 chromatin complex regulation, in FP-RMS.
    Journal
    |
    FOXO1 (Forkhead box O1) • ETS1 (ETS Proto-Oncogene 1) • PODXL (Podocalyxin) • FGF8 (Fibroblast Growth Factor 8) • IL4R (Interleukin 4 Receptor) • KDM3A (Lysine Demethylase 3A) • PAX3 (Paired Box 3)
    |
    PAX3-FOXO1 fusion
    over1year
    Long non-coding RNA LBX2-AS1 activates IL4R to promote glioblastoma metastasis and angiogenesis by binding to the transcription factor NFKB1. (PubMed, Folia Neuropathol)
    Rescue experiments illustrated that silencing IL4R or NFKB1 reversed the impact of forced LBX2-AS1 expression on GBM cells. This study revealed the mechanism of the LBX2-AS1/NFKB1/IL4R axis in driving GBM metastasis and angiogenesis, which may help to improve the regulatory network of GBM malignant progression and provide potential targets for GBM treatment.
    Journal
    |
    IL4R (Interleukin 4 Receptor)
    almost2years
    IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis. (PubMed, Theranostics)
    IL4R-Abx accumulated at tumors, heightened immune-stimulatory cells while reducing immune-suppressing cells, and hampered tumor growth and metastasis in mice more efficiently than Abx and Ctrl-Abx. These results indicate that IL4R-targeting allows enhancement of M2-macrophage shaping into M1-like phenotype by Abx through the ROS-HMGB1-TLR4 axis, improvement of antitumor immunity, and thereby inhibition of tumor growth and metastasis, presenting a new approach to cancer immunotherapy.
    Journal
    |
    HMGB1 (High Mobility Group Box 1) • TLR4 (Toll Like Receptor 4) • IL4 (Interleukin 4) • IL4R (Interleukin 4 Receptor)
    |
    albumin-bound paclitaxel
    2years
    Coculture of bacterial levans and evaluation of its anti-cancer activity against hepatocellular carcinoma cell lines. (PubMed, Sci Rep)
    The DNA damage values were significantly increased (P < 0.01) in treated liver cancer cell lines with levan M and Doxo. The results referred to the importance of each of the hydroxyl and carboxyl groups and the molecular weight in levans bioactivities.
    Preclinical • Journal
    |
    CCL20 (C-C Motif Chemokine Ligand 20) • IL10 (Interleukin 10) • CCR6 (C-C Motif Chemokine Receptor 6) • IL4R (Interleukin 4 Receptor)
    2years
    Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling. (PubMed, Nature)
    Finally, using PhasED-Seq we demonstrate the clinical value of pre- and on-treatment ctDNA levels for longitudinally refining cHL risk prediction, and for detection of radiographically occult minimal residual disease. Collectively, these results support the utility of noninvasive strategies for genotyping and dynamic monitoring of cHL as well as capturing molecularly distinct subtypes with diagnostic, prognostic, and therapeutic potential.
    Journal
    |
    IL13 (Interleukin 13) • IL4R (Interleukin 4 Receptor) • DNASE1L3 (Deoxyribonuclease 1 Like 3)
    over2years
    Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma. (PubMed, Cancer Res Commun)
    This study provides proof-of-principle that ultra-deep exome sequencing can be utilized to identify recurrent mutations in HRS cells and demonstrates the feasibility of snRNA-seq in the context of cHL. These studies provide the foundation for the further analysis of genomic variants in large cohorts of cHL patients.
    Journal
    |
    PIM1 (Pim-1 Proto-Oncogene) • CDH5 (Cadherin 5) • IL4R (Interleukin 4 Receptor)
    over2years
    Survival Outcomes in Recurrent Glioblastoma (rGBM) Patients Treated with a Single Intra-tumoral Administration of Bizaxofusp, an IL-4R-targeting Toxin, in a Phase IIb Trial (SNO 2023)
    In patients with rGBM, a single treatment of Bizaxofusp resulted in significantly improved OS compared to eligibility-matched ECA. High-dose Bizaxofusp was equally effective irrespective of IL4R expression. A Phase 3 registration trial will use a novel hybrid design with a propensity-matched ECA comprising two-thirds of the control arm, setting a new precedent for GBM clinical trials.
    Clinical • P2b data
    |
    IL4R (Interleukin 4 Receptor)
    |
    bizaxofusp (MDNA55)
    over2years
    Survival Outcomes in Recurrent Glioblastoma (rGBM) Patients Treated with a Single Intra-tumoral Administration of Bizaxofusp, an IL-4R-targeting Toxin, in a Phase IIb Trial (SNO 2023)
    In patients with rGBM, a single treatment of Bizaxofusp resulted in significantly improved OS compared to eligibility-matched ECA. High-dose Bizaxofusp was equally effective irrespective of IL4R expression. A Phase 3 registration trial will use a novel hybrid design with a propensity-matched ECA comprising two-thirds of the control arm, setting a new precedent for GBM clinical trials.
    Clinical • P2b data
    |
    IL4R (Interleukin 4 Receptor)
    |
    bizaxofusp (MDNA55)
    almost3years
    GENE EXPRESSION PROFILING OF T(14;18)-NEGATIVE CD23+ FOLLICLE CENTER LYMPHOMA DEMONSTRATES ACTIVATION OF THE IL4/JAK/STAT6 PATHWAY AND A ROLE IN ITS PATHOGENESIS (ICML 2023)
    GEP identified two distinct groups within t(14;18)-neg FL, indicating different stages of differentiation of the neoplastic B cells. FLnegmut shows activation of STAT6 pathway through upregulation of CD23 and IL4R and by enrichment in GSEA and correlates with CD23 expression. Constitutive activation of STAT6 and consequent upregulation of CD23 prevent ongoing B cell differentiation in FLnegmut, precluding the cells from exiting the GC and adopting the state of activated B cell.
    IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF17 (TNF Receptor Superfamily Member 17) • JAK1 (Janus Kinase 1) • CD22 (CD22 Molecule) • PAX5 (Paired Box 5) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • S100A8 (S100 Calcium Binding Protein A8) • IRF4 (Interferon regulatory factor 4) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • TYK2 (Tyrosine Kinase 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CD40 (CD40 Molecule) • FCGR1A (Fc Fragment Of IgG Receptor Ia) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • IL4 (Interleukin 4) • FCER2 (Fc Fragment Of IgE Receptor II) • FCRLA (Fc Receptor Like A) • IL4R (Interleukin 4 Receptor) • SLAMF7 (SLAM Family Member 7) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    |
    SOCS1 mutation
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel